An Oct. 28 column,

Stock Rotation Could Signal More Gains, misstated the location of Pacific Asset Management, the firm known as Pimco. The firm is located in Newport Beach, Calif., south of Los Angeles -- not "closer to San Francisco" as originally stated.

regrets the error.

(Corrected Oct. 29.)

Because of an editing error, an Oct. 28 column by James J. Cramer,

Viacom, Comcast Put in Bottoms, omitted his position in

JDS Uniphase

(JDSU:Nasdaq). He is long the stock.

regrets the error.

(Corrected Oct. 28)

A July 30 column,

Options and Microsoft's Special Dividend, incorrectly implied that the distribution date and the payable date of


(MSFT:Nasdaq) special dividend are one and the same. The distribution date is another term for the ex-dividend date.

regrets the error. (

Corrected Oct. 28


An Oct. 27 story,

A Taste for Tech Revives, incorrectly reported that

Sirius Satellite Radio

(SIRI:Nasdaq) earned $169 million, or 11 cents a share, in its third quarter. In fact, the company lost $169 million, or 14 cents a share, in the quarter.

regrets the error.

(Corrected Oct. 27)

An Oct. 26 story,

Tension Ahead of Pfizer Study Results, misstated the timing of a


(PFE:NYSE) presentation Wednesday at the CHEST 2004 Congress medical meeting in Seattle. The presentiation is scheduled for 1:30 p.m.-3 p.m. EDT, not 7:30 a.m.-9 a.m. as originally reported.

regrets the error.

(Corrected Oct. 26)

An Oct. 25 column by James Altucher,

WPT Stuck With Current Hand, mistakenly reported the company's IPO price. The August IPO priced at $8. Also, the company's deal with the Travel Channel is a seven-year deal that ends in 2009, not a nine-year deal.

regrets the errors.

(Corrected Oct. 26)

An Oct. 22 column by James Cramer,

Google: New Winner of the New World," might have given the impression Cramer was short stocks he spoke about in a speech in 2000. Cramer was not short those stocks at the time of the speech; to clarify, he was not short the stocks he spoke about until a later date.

(Clarified Oct. 22)

An Oct. 19 story, Climbs on Upgrade, mistakenly reported the date on which Avondale Partners analyst Frank Gristina started tallying the number of items listed on Overstock's auction site. Gristina reported that Overstock had 401 items listed on its auction site on Sept. 27, not on Sept. 7.

regrets the error.

(Corrected Oct. 19)

An Oct. 14 column,

Follow the End User Demand, by Cody Willard, omitted the fact that he is long



regrets the error.

(Corrected Oct. 15)

An Oct. 13 story,

Host Marriott Narrows Loss, mistakenly reported that

Host Marriott's

(HMT:NYSE) third-quarter 2004 funds from operations, or FFO, included a gain of about 2 cents a share from an insurance settlement. In fact, the gain was included in the company's third-quarter 2003 FFO.

regrets the error.

(Corrected Oct. 13)

An Oct. 6 story,

Keeley Fund Digs Deep for Winners, mistakenly described

J.M. Smucker

(SJM:NYSE) as having been spun off from

Procter & Gamble

(PG:NYSE). In fact, Smucker has never been part of P&G. The error arose in Mark Keeley's description of the fund's investment following a stock swap accompanying the transfer of P&G's Jif and Crisco brands to Smucker.

regrets the error.

(Corrected Oct. 8)

In an Oct. 6 column,

Navarre's Tech Twist Wins With Gurus, the sentence "Under this methodology, Lynch likes to see the P/E ratio remain 40" should have read "Under this methodology, Lynch likes to see the P/E ratio remain



regrets the error.

(Corrected Oct. 7)

A Sept. 23 story,

SEC Inquiry Least of American Pharma's Troubles, misstated the rating held by CIBC analyst Elliot Wilbur. He rates

American Pharmaceutical Partners

(APPX:Nasdaq) a sector performer, not overweight.

regrets the error.

(Corrected Oct. 8)

Because of an editing error, an Oct. 7 column by James J. Cramer,

Shorts Have No Clothes in Retail, omitted his position in

Urban Outfitters

(URBN:Nasdaq). He is long the stock.

regrets the error.

(Corrected Oct. 7)

An Oct. 6 story,

Off-Label Imbroglio Latest Concern for Drugmakers, mistakenly reported that


(DNA:NYSE) had never run afoul of the FDA's off-label marketing rules. In 1999, the biotech firm paid a $50 million fine for marketing human growth hormone for an unapproved use. To clarify, Genentech has never been accused of violating FDA off-label marketing rules for its cancer drug Rituxan, which is the subject of the subpoena issued Monday.

Also, SG Cowen no longer uses ratings on individual stocks, so analyst Eric Schmidt's strong buy rating is outdated.

regrets the errors.

(Corrected Oct. 6)

A Sept. 20 story,

IBM, Boeing in Military IT Alliance, misidentified Jim Albaugh as CEO of


(BA:NYSE). He actually heads up Boeing Integrated Defense Systems, which is based in St. Louis. The article also incorrectly reported Boeing's headquarters are in St. Louis. In fact, they are in Chicago.


regrets the errors.

(Corrected Oct. 6)